Cadila Shifts US Injectables Production From Plant After Tough FDA Inspection
Executive Summary
Expert investigators found many problems at Ahmedabad plant, warning letter and Form 483 report show.
You may also be interested in...
US FDA Investigators Focusing Inspections On Aseptic Processing Operations
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.
Zydus Cadila’s New Injectables Plant Could Help Blunt US Drug Shortages
Site switch also could trigger ANDA approvals sidelined as Moraiya plant recovers from US FDA warning letter.
The Quality Lowdown: Quality Vision Falls Short At Various US and Indian Facilities
Court overrides stem cell clinic’s dismissal of drug GMPs, the US FDA upbraids drug makers for quality unit shortfalls, and a variety of snafus trigger drug recalls.